<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2025-2-100-106</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-2492</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Rational approach to migraine attacks relief</article-title><trans-title-group xml:lang="ru"><trans-title>Рациональный подход к купированию приступов мигрени</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3833-532X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Табеева</surname><given-names>Г. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Tabeeva</surname><given-names>G. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней и нейрохирургии Института клинической медицины им. Н.В. Склифосовского </p><p>119021, Москва, ул. Россолимо, 11, стр. 1</p></bio><bio xml:lang="en"><p>Department of Nervous Diseases and Neurosurgery, Institute of Professional Education, N.V. Sklifosovsky Institute of Clinical Medicine </p><p>11, Rossolimo St., Build. 1, Moscow 119021</p></bio><email xlink:type="simple">grtabeeva@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>04</month><year>2025</year></pub-date><volume>17</volume><issue>2</issue><fpage>100</fpage><lpage>106</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tabeeva G.R., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Табеева Г.Р.</copyright-holder><copyright-holder xml:lang="en">Tabeeva G.R.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/2492">https://nnp.ima-press.net/nnp/article/view/2492</self-uri><abstract><p>Strategies against migraine attacks include the use of pharmacological agents that are both non-specific and specific for migraine. Despite the wide arsenal of pharmacological agents, effective pain relief is achieved in only one third of migraine patients. When choosing the optimal analgesics for each patient, several key characteristics of the drug should be considered: not only its analgesic effect, but also its ability to rapidly terminate concomitant symptoms without the need for additional analgesics. One of the justified strategies is the combination of specific and nonspecific agents or the use of ready-made combination preparations that allow a multimodal effect in migraine.</p></abstract><trans-abstract xml:lang="ru"><p>Стратегии лечения приступов мигрени включают использование неспецифических и специфических для мигрени фармакологических средств. Несмотря на широкий арсенал фармакологических препаратов, эффективное обезболивание достигается лишь у трети пациентов с мигренью. При выборе оптимального для каждого пациента обезболивания следует учитывать ряд ключевых свойств лекарственного средства: не только его анальгетическую активность, но и способность быстро купировать сопутствующие симптомы без необходимости использования дополнительного обезболивания. Одной из оправданных стратегий является комбинирование специфических и неспецифических средств или использование готовых комбинированных препаратов, которые позволяют обеспечить мультимодальные эффекты при мигрени. </p></trans-abstract><kwd-group xml:lang="ru"><kwd>мигрень</kwd><kwd>приступы мигрени</kwd><kwd>купирование приступов мигрени</kwd><kwd>триптаны</kwd><kwd>эрготамин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>migraine</kwd><kwd>migraine attacks</kwd><kwd>relief of migraine attacks</kwd><kwd>triptans</kwd><kwd>ergotamine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Ashina M. Migraine. N Engl J Med. 2020 Nov 5;383(19):1866-76. doi: 10.1056/NEJMra1915327</mixed-citation><mixed-citation xml:lang="en">Ashina M. Migraine. N Engl J Med. 2020 Nov 5;383(19):1866-76. doi: 10.1056/NEJMra1915327</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.</mixed-citation><mixed-citation xml:lang="en">GBD 2016 Neurology Collaborators. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 May;18(5):459-80. doi: 10.1016/S1474-4422(18)30499-X. Epub 2019 Mar 14.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202</mixed-citation><mixed-citation xml:lang="en">Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992 Aug;12(4):221-8; discussion 186. doi: 10.1046/j.1468-2982.1992.1204221.x</mixed-citation><mixed-citation xml:lang="en">Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992 Aug;12(4):221-8; discussion 186. doi: 10.1046/j.1468-2982.1992.1204221.x</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018 May;58 Suppl 1:4-16. doi: 10.1111/head.13300</mixed-citation><mixed-citation xml:lang="en">Dodick DW. A Phase-by-Phase Review of Migraine Pathophysiology. Headache. 2018 May;58 Suppl 1:4-16. doi: 10.1111/head.13300</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-30. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6.</mixed-citation><mixed-citation xml:lang="en">Dodick DW. Migraine. Lancet. 2018 Mar 31;391(10127):1315-30. doi: 10.1016/S0140-6736(18)30478-1. Epub 2018 Mar 6.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tepper SJ. History and Review of antiCalcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 Nov;58 Suppl 3:238-75. doi: 10.1111/head.13379. Epub 2018 Sep 22.</mixed-citation><mixed-citation xml:lang="en">Tepper SJ. History and Review of antiCalcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment. Headache. 2018 Nov;58 Suppl 3:238-75. doi: 10.1111/head.13379. Epub 2018 Sep 22.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Филатова ЕГ, Амелин АВ и др. Альтернативные и комплементарные методы лечения мигрени. Неврология, нейропсихиатрия, психосоматика. 2024;16(1):4-15. doi: 10.14412/2074-2711-2024-1-4-15</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Filatova EG, Amelin AV, et al. Alternative and complementary treatments for migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1):4-15. doi: 10.14412/2074-2711-2024-1-4-15 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18.</mixed-citation><mixed-citation xml:lang="en">Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021 Aug;17(8):501-14. doi: 10.1038/s41582-021-00509-5. Epub 2021 Jun 18.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018 Feb 1;19(1):10. doi: 10.1186/s10194-018-0839-1</mixed-citation><mixed-citation xml:lang="en">Katsarava Z, Mania M, Lampl C, et al. Poor medical care for people with migraine in Europe – evidence from the Eurolight study. J Headache Pain. 2018 Feb 1;19(1):10. doi: 10.1186/s10194-018-0839-1</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-95. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25.</mixed-citation><mixed-citation xml:lang="en">Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. Lancet. 2021 Apr 17;397(10283):1485-95. doi: 10.1016/S0140-6736(20)32160-7. Epub 2021 Mar 25.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10. Erratum in: Headache. 2019 Apr;59(4):650-1. doi: 10.1111/head.13506</mixed-citation><mixed-citation xml:lang="en">American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019 Jan;59(1):1-18. doi: 10.1111/head.13456. Epub 2018 Dec 10. Erratum in: Headache. 2019 Apr;59(4):650-1. doi: 10.1111/head.13506</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Bentivegna E, Onan D, Martelletti P. Unmet Needs in Preventive Treatment of Migraine. Neurol Ther. 2023 Apr;12(2):337-42. doi: 10.1007/s40120-023-00438-z.Epub 2023 Feb 4.</mixed-citation><mixed-citation xml:lang="en">Bentivegna E, Onan D, Martelletti P. Unmet Needs in Preventive Treatment of Migraine. Neurol Ther. 2023 Apr;12(2):337-42. doi: 10.1007/s40120-023-00438-z.Epub 2023 Feb 4.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024 Jan;41(1):1-13. doi: 10.1007/s12325-023-02650-7. Epub 2023 Nov 9.</mixed-citation><mixed-citation xml:lang="en">Bentivegna E, Galastri S, Onan D, Martelletti P. Unmet Needs in the Acute Treatment of Migraine. Adv Ther. 2024 Jan;41(1):1-13. doi: 10.1007/s12325-023-02650-7. Epub 2023 Nov 9.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi: 10.1016/j.bcp.2020.114147. Epub 2020 Jul 10.</mixed-citation><mixed-citation xml:lang="en">Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective. Biochem Pharmacol. 2020 Oct;180:114147. doi: 10.1016/j.bcp.2020.114147. Epub 2020 Jul 10.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010 Feb;50(2):256-63. doi: 10.1111/j.1526-4610.2009.01595.x. Epub 2009 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Bigal ME, Golden W, Buse D, et al. Triptan use as a function of cardiovascular risk. A population-based study. Headache. 2010 Feb;50(2):256-63. doi: 10.1111/j.1526-4610.2009.01595.x. Epub 2009 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81-92. doi: 10.1111/j.1526-4610.2012.02265.x. Epub 2012 Oct 18.</mixed-citation><mixed-citation xml:lang="en">Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: effects of sex, income, and headache features. Headache. 2013 Jan;53(1):81-92. doi: 10.1111/j.1526-4610.2012.02265.x. Epub 2012 Oct 18.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821-34. doi: 10.1111/head.12774. Epub 2016 May 3.</mixed-citation><mixed-citation xml:lang="en">Dodick DW, Loder EW, Manack Adams A, et al. Assessing Barriers to Chronic Migraine Consultation, Diagnosis, and Treatment: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. Headache. 2016 May;56(5):821-34. doi: 10.1111/head.12774. Epub 2016 May 3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Urtecho M, Wagner B, Wang Z, et al. A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes. Headache. 2023 Feb;63(2):185-201. doi: 10.1111/head.14430. Epub 2023 Jan 5.</mixed-citation><mixed-citation xml:lang="en">Urtecho M, Wagner B, Wang Z, et al. A qualitative evidence synthesis of patient perspectives on migraine treatment features and outcomes. Headache. 2023 Feb;63(2):185-201. doi: 10.1111/head.14430. Epub 2023 Jan 5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lipton RB, Stewart WF, Stone AM, et al; Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000 Nov 22-29;284(20):2599-605. doi: 10.1001/jama.284.20.2599</mixed-citation><mixed-citation xml:lang="en">Lipton RB, Stewart WF, Stone AM, et al; Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA. 2000 Nov 22-29;284(20):2599-605. doi: 10.1001/jama.284.20.2599</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80.</mixed-citation><mixed-citation xml:lang="en">Worthington I, Pringsheim T, Gawel MJ, et al; Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci. 2013 Sep;40(5 Suppl 3):S1-S80.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002;20(2):91-100. doi: 10.2165/00019053-200220020-00002</mixed-citation><mixed-citation xml:lang="en">Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics. 2002;20(2):91-100. doi: 10.2165/00019053-200220020-00002</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021 Dec;178(23):4588-607. doi: 10.1111/bph.15657. Epub 2021 Sep 26.</mixed-citation><mixed-citation xml:lang="en">Zobdeh F, Ben Kraiem A, Attwood MM, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol. 2021 Dec;178(23):4588-607. doi: 10.1111/bph.15657. Epub 2021 Sep 26.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008 Aug;28(8):877-86. doi: 10.1111/j.1468-2982.2008.01578.x. Epub 2008 May 5.</mixed-citation><mixed-citation xml:lang="en">Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia. 2008 Aug;28(8):877-86. doi: 10.1111/j.1468-2982.2008.01578.x. Epub 2008 May 5.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000</mixed-citation><mixed-citation xml:lang="en">Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs. 2010 Aug 20;70(12):1505-18. doi: 10.2165/11537990-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Dodick D, Lipton RB, Martin V, et al; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 May;44(5):414-25. doi: 10.1111/j.1526-4610.2004.04078.x</mixed-citation><mixed-citation xml:lang="en">Dodick D, Lipton RB, Martin V, et al; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004 May;44(5):414-25. doi: 10.1111/j.1526-4610.2004.04078.x</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Амелин АВ, Ахмадеева ЛР и др. Оптимизация купирования приступов мигрени. Неврология, нейропсихиатрия, психосоматика. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Amelin AV, Akhmadeeva LR, et al. Optimization of migraine attacks relief. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):126-33. doi: 10.14412/2074-2711-2023-2-126-133 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Tfelt-Hansen P, Pascual J, Ramadan N, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38. doi: 10.1177/0333102411417901</mixed-citation><mixed-citation xml:lang="en">Tfelt-Hansen P, Pascual J, Ramadan N, et al; International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia. 2012 Jan;32(1):6-38. doi: 10.1177/0333102411417901</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499</mixed-citation><mixed-citation xml:lang="en">Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache. 2007 Sep;47(8):1152-68. doi: 10.1111/j.1526-4610.2007.00849.x</mixed-citation><mixed-citation xml:lang="en">Pascual J, Mateos V, Roig C, et al. Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability. Headache. 2007 Sep;47(8):1152-68. doi: 10.1111/j.1526-4610.2007.00849.x</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Харитонова АА. Гастростаз при мигрени и эффективность противомигренозных средств. Неврология, нейропсихиатрия, психосоматика. 2024;16(1S):4-11. doi: 10.14412/2074-2711-2024-1S-4-11</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Kharitonova AA. Gastric stasis in migraine and the efficacy of antimigraine drugs. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(1S):4-11. doi: 10.14412/2074-2711-2024-1S-4-11 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37 Suppl 1:S15-25.</mixed-citation><mixed-citation xml:lang="en">Silberstein SD. The pharmacology of ergotamine and dihydroergotamine. Headache. 1997;37 Suppl 1:S15-25.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. J Pain Res. 2020 Apr 30;13:859-64. doi: 10.2147/JPR.S203650</mixed-citation><mixed-citation xml:lang="en">Shafqat R, Flores-Montanez Y, Delbono V, Nahas SJ. Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations. J Pain Res. 2020 Apr 30;13:859-64. doi: 10.2147/JPR.S203650</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184</mixed-citation><mixed-citation xml:lang="en">Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache. 2010 Oct;50(9):1507-10. doi: 10.1111/j.1526-4610.2010.01765.x</mixed-citation><mixed-citation xml:lang="en">Ahn AH. On the temporal relationship between throbbing migraine pain and arterial pulse. Headache. 2010 Oct;50(9):1507-10. doi: 10.1111/j.1526-4610.2010.01765.x</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-8.</mixed-citation><mixed-citation xml:lang="en">Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-8.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Табеева ГР, Косивцова ОВ, Ковальчук НА, Орлюк ТА. Рефрактерная мигрень. Неврология, нейропсихиатрия, психосоматика. 2024;16(2):76-86. doi: 10.14412/2074-2711-2024-2-76-86</mixed-citation><mixed-citation xml:lang="en">Tabeeva GR, Kosivtsova OV, Kovalchuk NA, Orlyuk TA. Refractory migraine. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16(2):76-86. doi: 10.14412/2074-2711-2024-2-76-86 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May;27(5):385-94. doi: 10.1007/s40263-013-0061-2</mixed-citation><mixed-citation xml:lang="en">Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May;27(5):385-94. doi: 10.1007/s40263-013-0061-2</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010 Sep;50(8):1353-61. doi: 10.1111/j.1526-4610.2010.01662.x. Epub 2010 Mar 29.</mixed-citation><mixed-citation xml:lang="en">Baron EP, Tepper SJ. Revisiting the role of ergots in the treatment of migraine and headache. Headache. 2010 Sep;50(8):1353-61. doi: 10.1111/j.1526-4610.2010.01662.x. Epub 2010 Mar 29.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939</mixed-citation><mixed-citation xml:lang="en">VanderPluym JH, Halker Singh RB, Urtecho M, et al. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15;325(23):2357-69. doi: 10.1001/jama.2021.7939</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Bosnalijek DOO, Product composition. Product monograph Nomigren, Bosnalijek, Sarajevo, 2007, 1-2. Available at: http://www.bosnalijek.com/productsL2e?c=zn&amp;zn=NOMIGREN (accessed 30.01.2018).</mixed-citation><mixed-citation xml:lang="en">Bosnalijek DOO, Product composition. Product monograph Nomigren, Bosnalijek, Sarajevo, 2007, 1-2. Available at: http://www.bosnalijek.com/productsL2e?c=zn&amp;zn=NOMIGREN (accessed 30.01.2018).</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008 Jul;33(7):404-16.</mixed-citation><mixed-citation xml:lang="en">Demaagd G. The pharmacological management of migraine, part 1: overview and abortive therapy. P T. 2008 Jul;33(7):404-16.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Miljkovic S, Smajlovic D, Tiric Campara M, et al. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar;22(1):17-22.</mixed-citation><mixed-citation xml:lang="en">Miljkovic S, Smajlovic D, Tiric Campara M, et al. The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura. Hippokratia. 2018 Jan-Mar;22(1):17-22.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
